{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoarthritis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"5ae3cd70-eacb-5c4c-98f5-dace0da22472","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2f24ab2e-2611-4016-9925-93962aff5756 --><h2>Changes</h2><!-- end field 2f24ab2e-2611-4016-9925-93962aff5756 -->","summary":null,"htmlStringContent":"<!-- begin item 4dabcb3d-612a-4d96-8d9f-5fc534f6e0f1 --><!-- begin field 4ab24aa5-3180-4c38-99aa-6e335e291f19 --><p><strong>June 2018 </strong>— reviewed. A literature search was conducted in May 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The lower age limit for the topic has been changed to 45 years. The topic has undergone major restructuring to improve navigation, clarity, and transparency. The management recommendations have been updated in line with the current literature including the updated National Institute for Health and Care Excellence (NICE) clinical guideline <em>Osteoarthritis: care and management</em> (2014). The Prescribing information section has been shortened and updated in line with current CKS style, and links to other relevant CKS topics have been added.</p><!-- end field 4ab24aa5-3180-4c38-99aa-6e335e291f19 --><!-- end item 4dabcb3d-612a-4d96-8d9f-5fc534f6e0f1 -->","topic":{"id":"de61cfe3-a7fc-50bd-87eb-af7e90b20bfc","topicId":"c9866707-687c-4314-bff3-ae71e0d7e669","topicName":"Osteoarthritis","slug":"osteoarthritis","lastRevised":"Last revised in June 2018","chapters":[{"id":"9674ea7a-b052-5c2f-a0a1-336c67e0622a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aec2334e-8ee7-5d04-902e-c9a904550f17","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6a895bdb-e3ce-53e5-a302-6bbca48a6e9f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5ae3cd70-eacb-5c4c-98f5-dace0da22472","slug":"changes","fullItemName":"Changes"},{"id":"2723ad88-c2c8-5b92-ac37-5d5af66e900a","slug":"update","fullItemName":"Update"}]},{"id":"3ffc0128-f379-5b16-bfbb-fe9c04753b07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"740484d6-e553-5d2a-bcbf-22e4b61e30c8","slug":"goals","fullItemName":"Goals"},{"id":"2ab52642-cd7c-5b7d-a3c9-911580e1911c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3bb32b14-2fda-58fa-b09c-cd98270c7adb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35eeb6be-f0dd-5cde-a148-b87e5da25be5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3a253c38-1fe5-581e-8eff-eb2e5225d071","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"06733eae-d1c5-59d1-a725-266721a216af","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3825aa8e-f0d5-5c9c-89b4-1898289f4fc9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"182bd361-b277-56da-ba91-aec64a5dbc1e","slug":"definition","fullItemName":"Definition"},{"id":"8696aed8-8dba-5a61-a12d-83015e11e6f3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"80accb52-81a2-5799-93cd-5e7582f72276","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c1ea97e2-1426-5b7d-bde9-716cb3c7eafa","slug":"complications","fullItemName":"Complications"},{"id":"274efaa2-3e84-556a-b637-e3465e12e5e3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"27d93353-f59d-560a-a997-442790b4886e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fb6bb640-6ea0-5e5d-ab1e-226ba7b3f1a5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3946b5ad-ac52-5fa8-aac6-2336526f17d7","slug":"assessment","fullItemName":"Assessment"},{"id":"258c85c0-fccc-5104-bd56-7b9ad61740f0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"431a0217-fdab-502e-926c-a37e20150d61","fullItemName":"Management","slug":"management","subChapters":[{"id":"281a0a54-9420-5c71-ab29-0e6ac788fdb5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"157c78c6-0823-59f1-be8e-37716aebc131","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3c945e6b-1050-57b1-8fb2-52d4675e3b20","slug":"topical-nsaids","fullItemName":"Topical NSAIDs"},{"id":"7859a51d-1efc-5b71-8547-74135120e0c1","slug":"topical-capsaicin","fullItemName":"Topical capsaicin"}]},{"id":"605232dc-8685-5f88-b393-460b958a4e26","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"376de13c-5458-5bd0-987d-d1998635c19a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"098b9a8a-7356-5cc6-8d8e-103f9f4b5c19","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"114aa4f2-a690-5db8-913f-ed5733b88ec7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4a226d2-7bc7-5f71-822a-bb2115a1e0da","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5a772c1-6d28-5056-becd-1d1b06be8907","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c56a97ce-4c02-5076-a99e-b3272c1e9bd4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7ad7c476-7017-5c96-bd7d-25890a8b6390","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6a895bdb-e3ce-53e5-a302-6bbca48a6e9f","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"1bb07135-6228-5506-8dc7-e4c416ace6c2","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 3a1cb7c0-24c0-4198-9d48-7f2ad84c7cb7 --><h3>Previous changes</h3><!-- end field 3a1cb7c0-24c0-4198-9d48-7f2ad84c7cb7 -->","summary":null,"htmlStringContent":"<!-- begin item 894ff446-49aa-48af-b51a-4631bd1c1533 --><!-- begin field 4c321816-7b60-4689-ba26-26f7403391ca --><p><strong>April 2015 </strong>— minor update. Update to the text to reflect a new law on drugs and impaired driving (Department for Transport, 2014).</p><p><strong>July 2014 </strong>— minor update. Update to the text to include advice from the MHRA regarding the safe use and disposal of fentanyl patches following reports of accidental exposures that have led to life-threatening adverse effects.</p><p><strong>June 2014</strong> — minor update. Update to the text to reflect the fact that tramadol has been reclassified as a Schedule 3 controlled drug.</p><p><strong>February 2014 </strong>— minor update. The prescribing information section has been updated to reflect new information from the manufacturer of piroxicam gel regarding reports of renal adverse effects.</p><p><strong>January 2014 </strong>— minor update. The text regarding the use of codeine during breastfeeding has been updated to reflect new guidance from the Medicines and Healthcare products Regulatory Agency (MHRA). Codeine is no longer recommended for breastfeeding mothers, and tramadol or dihydrocodeine are preferred alternatives.</p><p><strong>April 2013</strong> — reviewed. A literature search was conducted in March 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2012</strong> — minor update. Information from the manufacturer's Summary of Product Characteristics (SPC) about the possible interaction between pantoprazole and warfarin has been added to drug interactions. Information from the British National Formulary about the potentially serious interaction between proton pump inhibitors (PPIs) and protease inhibitors (atazanavir and saquinavir) has also been added. Issued in January 2012.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011</strong> — technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations.</p><p><strong>September 2010 </strong>— minor update. The European League against Rheumatism (EULAR) evidence-based recommendations for the diagnosis of knee osteoarthritis have been added to the Diagnosis section. The Medicines and Healthcare products Regulatory Agency (MHRA) has also advised that topical ketoprofen is associated with a risk of photosensitivity reactions. Issued in September 2010.</p><p><strong>June 2010</strong> — minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Glucosamine sulphate is now available as a licensed medicinal product. Issued in July 2010.</p><p><strong>July 2009</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors. Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential. Issued in July 2009.</p><p><strong>June 2009</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded prescribers of the risk of photosensitivity reactions for people using topical ketoprofen. The prescriptions for intra-articular corticosteroids have also been updated. Issued in June 2009.</p><p><strong>April to August 2008</strong> — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Information on management of suspected infection of a prosthetic joint is no longer included. The major changes to recommendations reflect National Institute for Health and Care Excellence (NICE) guidance.</p><p><strong>January 2008</strong> — minor update. Prescription for glucosamine added. Issued in January 2008.</p><p><strong>December 2007</strong> — minor update. Glucosamine is now available as a licensed medicinal product. Issued in December 2007.</p><p><strong>July 2007</strong> — minor update to drug rationales. Issued in August 2007.</p><p><strong>July 2006 </strong>— minor update to drug rationales. Issued in July 2006.</p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p><strong>February 2005</strong> — rewritten. Validated in June 2005 and issued in July 2005.</p><p><strong>September 2004</strong> — updated due to the withdrawal of rofecoxib. Issued in September 2004.</p><p><strong>March 2002</strong> — updated to incorporate referral advice from the National Institute for Health and Care Excellence (NICE). Issued in April 2002.</p><p><strong>September 2001</strong> — reviewed. Validated in November 2001 and issued in April 2002.</p><p><strong>June 1999</strong> — written. Validated in October 1999 and issued in January 2000.</p><!-- end field 4c321816-7b60-4689-ba26-26f7403391ca --><!-- end item 894ff446-49aa-48af-b51a-4631bd1c1533 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}